406 related articles for article (PubMed ID: 32884236)
21. Development of Niosomal Vesicles Loaded Mometasone Furoate Gel for Transdermal Delivery and its Evaluation.
Rane BR; Chavan PY; Kate NS; Jain AS
Recent Adv Drug Deliv Formul; 2023; 17(4):300-313. PubMed ID: 37974444
[TBL] [Abstract][Full Text] [Related]
22. Co-delivery of miRNA-15a and miRNA-16-1 using cationic PEGylated niosomes downregulates Bcl-2 and induces apoptosis in prostate cancer cells.
Ghaffari M; Kalantar SM; Hemati M; Dehghani Firoozabadi A; Asri A; Shams A; Jafari Ghalekohneh S; Haghiralsadat F
Biotechnol Lett; 2021 May; 43(5):981-994. PubMed ID: 33515341
[TBL] [Abstract][Full Text] [Related]
23. [Induction of differentiation by ginsenoside Rh2 in hepatocarcinoma cell SMMC-7721].
Zeng XL; Tu ZG
Ai Zheng; 2004 Aug; 23(8):879-84. PubMed ID: 15301707
[TBL] [Abstract][Full Text] [Related]
24. In vitro Development of Controlled-Release Nanoniosomes for Improved Delivery and Anticancer Activity of Letrozole for Breast Cancer Treatment.
Ahmadi S; Seraj M; Chiani M; Hosseini S; Bazzazan S; Akbarzadeh I; Saffar S; Mostafavi E
Int J Nanomedicine; 2022; 17():6233-6255. PubMed ID: 36531115
[TBL] [Abstract][Full Text] [Related]
25. Formulation and Evaluation of Niosomal in situ Nasal Gel of a Serotonin Receptor Agonist, Buspirone Hydrochloride for the Brain Delivery via Intranasal Route.
Mathure D; Madan JR; Gujar KN; Tupsamundre A; Ranpise HA; Dua K
Pharm Nanotechnol; 2018; 6(1):69-78. PubMed ID: 29380709
[TBL] [Abstract][Full Text] [Related]
26. Growth Factor-Loaded Nano-niosomal Gel Formulation and Characterization.
Moghassemi S; Hadjizadeh A; Hakamivala A; Omidfar K
AAPS PharmSciTech; 2017 Jan; 18(1):34-41. PubMed ID: 27502406
[TBL] [Abstract][Full Text] [Related]
27. Influence of a niosomal formulation on the oral bioavailability of acyclovir in rabbits.
Attia IA; El-Gizawy SA; Fouda MA; Donia AM
AAPS PharmSciTech; 2007 Dec; 8(4):E106. PubMed ID: 18181527
[TBL] [Abstract][Full Text] [Related]
28. Increased antitumor efficacy of ginsenoside Rh
Xia X; Tao J; Ji Z; Long C; Hu Y; Zhao Z
Drug Deliv; 2020 Dec; 27(1):1369-1377. PubMed ID: 32998576
[TBL] [Abstract][Full Text] [Related]
29. Co-encapsulation of hydrophilic and hydrophobic drugs into niosomal nanocarrier for enhanced breast cancer therapy: In silico and in vitro studies.
Amiri S; Pashizeh F; Moeinabadi-Bidgoli K; Eyvazi Y; Akbari T; Salehi Moghaddam Z; Eskandarisani M; Farahmand F; Hafezi Y; Nouri Jevinani H; Seif M; Mousavi-Niri N; Chiani M; Tavakkoli Yaraki M
Environ Res; 2023 Dec; 239(Pt 2):117292. PubMed ID: 37806480
[TBL] [Abstract][Full Text] [Related]
30. PEGylated Liposomes of Meloxicam: Optimization by Quality by Design, in vitro Characterization and Cytotoxicity Evaluation.
Shaji J; Menon I
Pharm Nanotechnol; 2017; 5(2):119-137. PubMed ID: 28462699
[TBL] [Abstract][Full Text] [Related]
31. Antitumoral Activity of (20R)- and (20S)-Ginsenoside Rh2 on Transplanted Hepatocellular Carcinoma in Mice.
Lv Q; Rong N; Liu LJ; Xu XL; Liu JT; Jin FX; Wang CM
Planta Med; 2016 May; 82(8):705-11. PubMed ID: 27163230
[TBL] [Abstract][Full Text] [Related]
32. Preparation and evaluation of optimized zolmitriptan niosomal emulgel.
Mohamed MI; Abdelbary AA; Kandil SM; Mahmoud TM
Drug Dev Ind Pharm; 2019 Jul; 45(7):1157-1167. PubMed ID: 30919700
[No Abstract] [Full Text] [Related]
33. Formulation and investigation of pilocarpine hydrochloride niosomal gels for the treatment of glaucoma: intraocular pressure measurement in white albino rabbits.
Jain N; Verma A; Jain N
Drug Deliv; 2020 Dec; 27(1):888-899. PubMed ID: 32551978
[TBL] [Abstract][Full Text] [Related]
34. New generation of drug delivery systems based on ginsenoside Rh2-, Lysine- and Arginine-treated highly porous graphene for improving anticancer activity.
Zare-Zardini H; Taheri-Kafrani A; Amiri A; Bordbar AK
Sci Rep; 2018 Jan; 8(1):586. PubMed ID: 29330486
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics and pharmacodynamics of Rh2 and aPPD ginsenosides in prostate cancer: a drug interaction perspective.
Ben-Eltriki M; Shankar G; Tomlinson Guns ES; Deb S
Cancer Chemother Pharmacol; 2023 Dec; 92(6):419-437. PubMed ID: 37709921
[TBL] [Abstract][Full Text] [Related]
36. Enhancement of 8-methoxypsoralen topical delivery via nanosized niosomal vesicles: Formulation development, in vitro and in vivo evaluation of skin deposition.
Kassem AA; Abd El-Alim SH; Asfour MH
Int J Pharm; 2017 Jan; 517(1-2):256-268. PubMed ID: 27956194
[TBL] [Abstract][Full Text] [Related]
37. Ginsenoside Rh2: A shining and potential natural product in the treatment of human nonmalignant and malignant diseases in the near future.
Guan W; Qi W
Phytomedicine; 2023 Sep; 118():154938. PubMed ID: 37406390
[TBL] [Abstract][Full Text] [Related]
38. Design and optimization various formulations of PEGylated niosomal nanoparticles loaded with phytochemical agents: potential anti-cancer effects against human lung cancer cells.
Shahbazi R; Jafari-Gharabaghlou D; Mirjafary Z; Saeidian H; Zarghami N
Pharmacol Rep; 2023 Apr; 75(2):442-455. PubMed ID: 36859742
[TBL] [Abstract][Full Text] [Related]
39. Rh2 or its aglycone aPPD in combination with docetaxel for treatment of prostate cancer.
Musende AG; Eberding A; Jia W; Ramsay E; Bally MB; Guns ET
Prostate; 2010 Sep; 70(13):1437-47. PubMed ID: 20687217
[TBL] [Abstract][Full Text] [Related]
40. (20S)-Protopanaxadiol Ginsenosides Induced Cytotoxicity via Blockade of Autophagic Flux in HGC-27 Cells.
Han Q; Han L; Tie F; Wang Z; Ma C; Li J; Wang H; Li G
Chem Biodivers; 2020 Jul; 17(7):e2000187. PubMed ID: 32384197
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
